Building Blocks

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>5-(Chlorosulfonyl)-2-ethoxybenzoic acid is a synthetic drug that inhibits the enzyme phosphodiesterase type 5 (PDE5), which is responsible for degradation of cyclic guanosine monophosphate (cGMP). It has been shown to be effective in the treatment of erectile dysfunction, with improved efficacy and reduced side effects when compared to sildenafil. 5-(Chlorosulfonyl)-2-ethoxybenzoic acid belongs to a class of drugs called phosphodiesterase inhibitors. Studies have found that it increases the duration and quality of erections by inhibiting PDE5, an enzyme that breaks down cGMP. This inhibition leads to an increase in cGMP levels, which relaxes smooth muscle cells in the corpus cavernosum and causes increased blood flow into the penis.</p>

<p>Versatile small molecule scaffold</p>

<p>2-(2-Methoxyethoxy)propanoic acid is a metabolite of clofibrate, a medication used to treat high cholesterol. It is also a metabolite of the drugs 2-methoxyethanol and 2-methoxyacetic acid. This metabolite has been shown to be an agonist for protein kinase C (PKC) isoforms alpha and gamma (PKA). It also acts as a monocarboxylic acid and has been shown to induce a syndrome in animals.</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Racemic 5-Hydroxymethyl Tolterodine is an industrial chemical that can be used in the production of fesoterodine. It is a racemic form, which means it has two forms that are mirror images of each other, and cannot be separated. This chemical is produced by the reaction of tolterodine with acetone and isobutyric acid in an organic solvent. The yields are dependent on the type of reagents used, such as deacyl and intermediates. Racemic 5-Hydroxymethyl Tolterodine crystallizes as a white powder and has a melting point of 104°C. It can be chiral, meaning it has two different forms that are not superimposable on one another. Racemic 5-Hydroxymethyl Tolterodine utilises isobutyryl chloride as an intermediate in its synthesis process.br&gt;br&gt;</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>2-Bromo-4-(trifluoromethoxy)anisole is a chemical that is metabolized to the active metabolites 2-bromo-4-(trifluoromethoxy)-phenol and 4-(trifluoromethoxy)benzoic acid. These metabolites are conjugated with glucuronic acid and excreted in urine. The mechanism of action of 2-bromo-4-(trifluoromethoxy)anisole is not well understood, but it has been shown to be effective against Salicylic acid and salicylic acid conjugates. This chemical also has a radioactive component, which can be used for diagnostic purposes.</p>

<p>Versatile small molecule scaffold</p>

<p>2-Benzyl-5-iodopyridazin-3(2H)-one is an arylating agent that is used in the synthesis of pharmaceuticals and dyestuffs. The reaction is usually carried out at high temperatures, but can also be performed at room temperature. The product yield is usually high, but can be increased by using activated aryl halides as the starting material. The reaction temperature may require adjustment depending on the reactivity of the substituent groups present.</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>ML335 is a selective inhibitor of the enzyme fatty acid amide hydrolase (FAAH), which is responsible for the degradation of endogenous cannabinoids. ML335 has been shown to inhibit FAAH with an IC50 value of 0.2 μM, and thereby increase the levels of endocannabinoids in mice and rats. This compound also binds to other basic proteins, including voltage-gated potassium channels, and may have analgesic effects as a result. The activation of these channels leads to increased neuronal excitability and pain relief. It is thought that ML335 could be used for chronic pain treatment due to its ability to inhibit FAAH and its downstream effects on other proteins.</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>(R)-1-(4-Ethoxyphenyl)ethanol is a chiral alcohol that has been shown to be an optimal substrate for the asymmetric catalytic hydrogenation of prochiral olefins. This compound is also known to be a prochiral molecule, and thus can exist in two forms, (R)- and (S)-enantiomers. The reaction can be carried out at various pH levels, with optimum activity occurring at pH 6-8. The morphology of the catalytic material is dependent on the type of metal used as a catalyst. The chirality of the substrate affects the stereospecificity of the reaction.</p>

<p>Methyl 4-(bromoethynyl)benzoate is a cross-coupling reaction that is used to synthesize alkynyl compounds. It is an efficient synthesis that can be carried out with toluene and unsymmetrical bromides as the substrates. This process can also be carried out in the presence of a catalyst, such as palladium chloride, to promote the reaction. The reaction has been shown to produce high yields of desired products with good enantioselectivity.</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>3-[(4-Ethoxyphenyl)sulfamoyl]benzoic acid is a synthetic small molecule that is used as a research tool to study protein interactions. It has been shown to inhibit the activity of ion channels, including potassium and sodium channels. 3-[(4-Ethoxyphenyl)sulfamoyl]benzoic acid also binds to the receptor and can activate it by inducing conformational changes in the receptor, which leads to an increase in calcium influx. This ligand has been used as a pharmacological tool for studying G-protein coupled receptors. The compound was isolated from a bacterial strain, Pseudomonas putida, and was first reported in 1974. 3-[(4-Ethoxyphenyl)sulfamoyl]benzoic acid has CAS number 325721-18-4 and is available with high purity.</p>

<p>3-[Methyl(phenyl)sulfamoyl]benzoic acid is a secondary metabolite that is isolated from the medicinal plant, Acacia mollissima. It is a white powder with a melting point of about 138°C. 3-[Methyl(phenyl)sulfamoyl]benzoic acid has been shown to have antibacterial activity against Gram-positive bacteria and some Gram-negative bacteria. 3-[Methyl(phenyl)sulfamoyl]benzoic acid also possesses antiviral activity and may inhibit the synthesis of DNA and RNA, as well as protein synthesis. The safety of 3-[Methyl(phenyl)sulfamoyl]benzoic acid has not been evaluated in humans, but it has been shown to be non-toxic in animal studies.</p>

<p>3-[(4-Methoxyphenyl)sulfamoyl]-4-methylbenzoic acid is a synthetic, water soluble and stable compound that is used in the modification of complex carbohydrates. It has been shown to have good reactivity with glycosylation, methylation, click chemistry, polysaccharide, fluorination, and saccharide. 3-[(4-Methoxyphenyl)sulfamoyl]-4-methylbenzoic acid can be used for the synthesis of oligosaccharides or monosaccharides. This compound is also available in various purities and custom synthesis.</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>5-(4-Chloro-3-nitrobenzenesulfonamido)-2-hydroxybenzoic acid is a research tool for the study of ion channels and their ligands. It is an inhibitor of cell proliferation, and has been shown to be a potent activator of a number of G protein coupled receptors. The molecule can be used in pharmacological studies as well as in the development of pharmaceutical drugs. 5-(4-Chloro-3-nitrobenzenesulfonamido)-2-hydroxybenzoic acid is a white powder that is soluble in water. It has been purified to &gt;95% purity and has no detectable impurities.</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Biphenyl-2,3,4,5-tetracarboxylic acid dianhydride (BPIPP) is a small molecule that has been shown to be effective in the treatment of chronic diarrhea. It is also able to prevent malignant brain tumors and colorectal carcinomas. BPIPP inhibits intracellular cyclic guanosine monophosphate (cGMP) levels and activates protein kinase G (PKG), which causes an increase in cAMP levels. The increase in cAMP levels is responsible for the decrease in blood pressure. BPIPP also decreases camp levels and increases fluorescence efficiency. With this drug, it was possible to use a more efficient method to measure plasma concentrations of BPIPPA than with other methods.</p>

<p>Versatile small molecule scaffold</p>

<p>1-(5-Methoxypyridin-2-yl)ethanone is a reactive compound that has been shown to bind to hemoglobin in the red blood cells of sickle cell disease patients. This binding leads to alterations in the shape of the erythrocytes, which causes them to clump together and form clots. The affinity of this compound for hemoglobin is much higher than that of other compounds tested, such as acetaminophen or benzoic acid. 1-(5-Methoxypyridin-2-yl)ethanone has been studied for its use as a long-acting hypoxic agent that may be used in conjunction with oxygen therapy for patients with pathological conditions such as sickle cell disease or pulmonary hypertension. This drug has also been hypothesized to increase levels of adenosine triphosphate (ATP) in erythrocytes and reduce oxidative stress by inhibiting the production of free radicals.</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>